Literature DB >> 11134280

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.

R Sabbe1, G R Picchio, C Pastore, O Chaloin, O Hartley, R Offord, D E Mosier.   

Abstract

N-terminal modifications of the chemokine RANTES bind to C-C chemokine receptor 5 (CCR5) and block human immunodeficiency virus type 1 (HIV-1) infection with greater efficacy than native RANTES. Modified RANTES compounds induce rapid CCR5 internalization and much slower receptor reexpression than native RANTES, suggesting that receptor sequestration is one mode of anti-HIV activity. The rates of CCR5 internalization and reexpression were compared using the potent n-nonanoyl (NNY)-RANTES derivative and CD4(+) T cells derived from donors with different CCR5 gene polymorphisms. NNY-RANTES caused even more rapid receptor internalization and slower reexpression than aminooxypentane (AOP)-RANTES. Polymorphisms in the promoter and coding regions of CCR5 significantly affected the receptor reexpression rate after exposure of cells to NNY-RANTES. These observations may be relevant for understanding the protective effects of different CCR5 genotypes against HIV-1 disease progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134280      PMCID: PMC113963          DOI: 10.1128/JVI.75.2.661-671.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

4.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

5.  Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.

Authors:  S Mummidi; M Bamshad; S S Ahuja; E Gonzalez; P M Feuillet; K Begum; M C Galvis; V Kostecki; A J Valente; K K Murthy; L Haro; M J Dolan; J S Allan; S K Ahuja
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

6.  An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  A L Edinger; T L Hoffman; M Sharron; B Lee; Y Yi; W Choe; D L Kolson; B Mitrovic; Y Zhou; D Faulds; R G Collman; J Hesselgesser; R Horuk; R W Doms
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

Authors:  J F Berson; D Long; B J Doranz; J Rucker; F R Jirik; R W Doms
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

8.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

9.  Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist.

Authors:  A E Proudfoot; C A Power; A J Hoogewerf; M O Montjovent; F Borlat; R E Offord; T N Wells
Journal:  J Biol Chem       Date:  1996-02-02       Impact factor: 5.157

10.  CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS).

Authors:  D H McDermott; P A Zimmerman; F Guignard; C A Kleeberger; S F Leitman; P M Murphy
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  17 in total

1.  Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Authors:  Heather A Pilch-Cooper; Scott F Sieg; Thomas J Hope; Ann Koons; Jean-Michel Escola; Robin Offord; Ronald S Veazey; Donald E Mosier; Brian Clagett; Kathy Medvik; Julie K Jadlowsky; Mark R Chance; Janna G Kiselar; James A Hoxie; Ronald G Collman; Nadeene E Riddick; Valentina Mercanti; Oliver Hartley; Michael M Lederman
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

2.  Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Authors:  Hubert Gaertner; Fabrice Cerini; Jean-Michel Escola; Gabriel Kuenzi; Astrid Melotti; Robin Offord; Irène Rossitto-Borlat; Rebecca Nedellec; Janelle Salkowitz; Guy Gorochov; Donald Mosier; Oliver Hartley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-12       Impact factor: 11.205

3.  Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody.

Authors:  Pierre Portalès; Sylvie Fabre; Thierry Vincent; Caroline Desmetz; Brigitte Réant; Danièle Noël; Jacques Clot; Christian Jorgensen; Pierre Corbeau
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

4.  Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent.

Authors:  Nathalie Signoret; Lindsay Hewlett; Silène Wavre; Annegret Pelchen-Matthews; Martin Oppermann; Mark Marsh
Journal:  Mol Biol Cell       Date:  2004-12-09       Impact factor: 4.138

5.  Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Authors:  Jiehua Zhou; Sangeetha Satheesan; Haitang Li; Marc S Weinberg; Kevin V Morris; John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2015-03-05

Review 6.  [Genetic susceptibility to infections].

Authors:  S J Ott; S Schreiber
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

7.  PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Authors:  Tatsuyoshi Kawamura; Shannon E Bruse; Awet Abraha; Makoto Sugaya; Oliver Hartley; Robin E Offord; Eric J Arts; Peter A Zimmerman; Andrew Blauvelt; Shannon E Bruce
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.

Authors:  Oliver Hartley; Karim Dorgham; Danielle Perez-Bercoff; Fabrice Cerini; Anouk Heimann; Hubert Gaertner; Robin E Offord; Gianfranco Pancino; Patrice Debré; Guy Gorochov
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Authors:  Cristina Pastore; Gastón R Picchio; Francesco Galimi; Richard Fish; Oliver Hartley; Robin E Offord; Donald E Mosier
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

10.  Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.

Authors:  Julie M Decker; Kenneth P Zammit; Juliet L Easlick; Mario L Santiago; Denise Bonenberger; Beatrice H Hahn; Olaf Kutsch; Frederic Bibollet-Ruche
Journal:  Virology       Date:  2009-09-12       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.